AusperBio Secures $50 Million Oversubscribed Series B+ Financing to Advance Development of AHB-137 for Functional Cure of Chronic Hepatitis B

On May 28, in San Francisco, AusperBio (collectively referred to as AusperBio), a private clinical biotechnology company committed to advancing targeted oligonucleotide therapies for the functional cure of chronic hepatitis B (CHB), announced the completion of a $50 million oversubscribed Series B+ financing round. The financing was led by an existing industry-leading venture capital firm, with participation from Qiming Venture Partners, CDH Investments, YuanBio Venture Capital, Sherpa Healthcare Partners, and Shanghai Hankang Private Equity Fund Management Co., Ltd.Powerfully participated. In July 2024, the company completedUS$37 million in Series A financing, and US$73 million in Series B financing completed in December 2024, means the company has completed three rounds of financing totaling US$160 million within a year.（AusperBio Completes $37 Million Series A Financing, Xincheng Fund Invests for 3 Consecutive Rounds）

This financing round follows AusperBio's Series B funding completed in December 2024, reflecting continued investor confidence in the company’s leading product, proprietary platform, and strategic direction. The proceeds will support the ongoing clinical development of AHB-137, a novel unconjugated antisense oligonucleotide for chronic hepatitis B (CHB), including planned Phase II trials outside mainland China. The funding will also expand commercial manufacturing partnerships and support the company’s long-term pipeline growth.

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, said:"We are deeply honored to have the continued support of our investors. This is a strong vote of confidence in our vision and the progress we have made so far. This new funding provides us with the momentum to advance AHB-137 into the next stage of global development. We remain committed to our mission of delivering functional cures for chronic hepatitis B and bringing life-changing therapies to patients worldwide."

Chris Yang, Ph.D., Co-founder and CSO of AusperBio, stated:"We are very encouraged by the latest progress of AHB-137, especially the positive Phase IIb data announced at the EASL conference in Amsterdam. With the strong support of investors, the AusperBio team is fully motivated to continue our clinical strategy and efforts to bring new treatment options to patients with chronic hepatitis B."

AusperBio is committed to providing patient-centered innovation, aiming to reduce the global health burden of chronic hepatitis B and transform the treatment paradigm for this serious chronic disease.